ISSN: 2754-4931

Journal of Gastroenterology & Hepatology Reports

SCIENTIFIC Research and Community

Research Article

Open Access

Pulmonary Vascular Complications in Liver Disease: A Comprehensive Review of Porto-Pulmonary Hypertension and Hepatopulmonary Syndrome with Illustrative Case Studies

Ritesh Bhandari[1], Muhammad M Javaid[2,3,4], Jack Shembrey[5,6], Pratima Gurung[7] and Adel Ekladious[8,9,10]*

[1]Department of Gastroenterology, Alice Springs Hospital, Alice Springs, Northern Territory, Australia

[2]Monash Rural Health Mildura, Monash University, Victoria, Australia

[3]Department of Renal Medicine, Woodlands Health, Singapore

[4]School of Medicine, Deakin University, Victoria, Australia

[5]Department of Infectious Disease, Alice Springs Hospital, Alice Springs, Northern Territory, Australia

[6]Department of Medicine, University Hospital Geelong, Geelong, Victoria, Australia

[7]Department of General Medicine, Nepean Hospital, Kingswood, NSW, Australia

[8]Department of General Medicine and Acute Assessment Unit, Canberra Hospital, Canberra, ACT, Australia

[9]Faculty of Health and Medical Sciences, University of Western Australia, Perth, Western Australia, Australia

[10]ANU College of Health and Medicine, Australian National University, Canberra, ACT, Australia

ABSTRACT

Background: Porto-pulmonary hypertension (PoPH) and hepatopulmonary syndrome (HPS) are significant pulmonary vascular complications in liver disease patients. Understanding their distinct features is crucial for optimal care.

Objectives: To provide an updated overview of PoPH and HPS, compare these conditions, and highlight diagnostic and treatment challenges using illustrative case studies.

Methods: A comprehensive literature review was conducted using PubMed, Embase, and Cochrane databases. Two case studies illustrate key clinical features and management considerations.

Results: Orthotopic liver transplantation (OLT) generally improves outcomes more consistently in HPS than in PoPH. Appropriate bridging therapy can significantly improve PoPH prognosis prior to OLT. Case studies highlight these approaches, including an atypical HPS presentation with acute liver injury, Budd-Chiari syndrome, and portal hypertension without pre-existing cirrhosis.

Conclusion: PoPH and HPS present distinct challenges in liver disease. Early recognition, accurate diagnosis, and tailored management strategies are crucial for improving outcomes. Clinicians must maintain a high index of suspicion for these complications, even in atypical presentations, to ensure timely diagnosis and optimal management.

***Corresponding author**

Adel Ekladious, Department of General Medicine and Acute Assessment Unit, Canberra Hospital, Canberra, ACT, Australia.

Received: November 02, 2024; **Accepted:** November 11, 2024; **Published:** December 24, 2024

Keywords: Porto Pulmonary Hypertension, Hepatopulmonary Syndrome, Liver Cirrhosis, Pulmonary Hypertension, Liver Transplantation

List of Acronyms

PoPH: Porto-Pulmonary Hypertension
HPS: Hepatopulmonary Syndrome
OLT: Orthotopic Liver Transplantation
mPAP: Mean pulmonary artery pressure
PVR: Pulmonary Vascular Resistance
PAWP: Pulmonary Artery Wedge Pressure
PASP: Pulmonary Artery Systolic Pressure
PAH: Pulmonary Artery Hypertension
MELD: Model for End-Stage Liver Disease
IPVD: Intrapulmonary Vascular Dilatation

Introduction

Liver disease, a global health concern affecting millions, can lead to severe systemic complications. Among these, pulmonary vascular complications, particularly Porto-pulmonary Hypertension (PoPH) and Hepatopulmonary Syndrome (HPS), present unique challenges.

PoPH and HPS are distinct entities with different pathophysiological mechanisms:

- **PoPH:** Pulmonary arterial hypertension in the setting of portal hypertension
- **HPS:** Intrapulmonary vascular dilatations leading to abnormal gas exchange

These complications significantly impact patient outcomes, quality of life, and survival rates. They also influence liver transplantation eligibility and post-transplant outcomes, emphasizing the need for early detection and appropriate management.

Despite advancements, challenges persist in early diagnosis, clinical presentation variability, and management, especially during the peri-transplant period.

This review provides a comprehensive overview of PoPH and HPS, focusing on:

1. Pathophysiology
2. Clinical presentation
3. Diagnostic approaches
4. Current management strategies

We compare these entities, highlight key differences for clinical decision-making and explore recent treatment advances.

To illustrate the clinical relevance and challenges, we present two case studies. These case studies illustrate the clinical relevance and challenges, including an atypical HPS presentation with acute liver injury and Budd-Chiari syndrome.

By synthesizing current literature and providing real-world examples, this review aims to enhance clinicians' understanding of PoPH and HPS, ultimately improving patient care in the complex intersection of hepatic and pulmonary vascular diseases.

Methodology

This review employed a systematic approach to analyse literature on Porto-pulmonary Hypertension (PoPH) and Hepatopulmonary Syndrome (HPS) in liver disease.

Literature Search

- **Databases:** PubMed/MEDLINE, Embase, Cochrane Library
- **Timeframe:** January 2014 to September 2024
- **Key terms:** "Pulmonary vascular complications," "Liver disease," "Porto-pulmonary hypertension," "Hepatopulmonary syndrome," "Cirrhosis," "Pulmonary arterial hypertension," "Gas exchange abnormalities"

Inclusion Criteria

- Original research, systematic reviews, meta-analyses, clinical guidelines
- Adult population focus
- Studies on epidemiology, pathophysiology, diagnosis, treatment, or prognosis of PoPH/HPS

Exclusion Criteria

- Paediatric population focus

Two illustrative case studies from our clinical practice are included to provide real-world context, highlighting unique presentations and management challenges.

Overview of Pulmonary Vascular Complications in Liver Disease

Porto-pulmonary Hypertension (PoPH)

To illustrate the clinical presentation, diagnostic approach, and management of PoPH, we will present a case study at the end of this section.

Definition and Epidemiology

Porto-pulmonary Hypertension (PoPH) is defined as pulmonary arterial hypertension associated with portal hypertension, with or without advanced liver disease [1, 2]. To diagnose PoPH, the following criteria must be met:

- Evidence of portal hypertension, which can be suggested by signs such as splenomegaly, thrombocytopenia, portosystemic shunts, oesophageal varices, or portal vein issues, or confirmed through hemodynamic measurements, without necessarily having cirrhosis; and
- Mean pulmonary artery pressure (mPAP) > 20 mmHg
- Pulmonary vascular resistance (PVR) ≥ 2 Wood units (WU)
- Pulmonary artery wedge pressure (PAWP) ≤ 15 mmHg

The prevalence of PoPH among patients with cirrhosis ranges from 2% for those not on a liver transplant list to 16% for those with end-stage disease on transplant list. PoPH is found in approximately 2% to 10% of individuals with portal hypertension and accounts for about 5.3% to 10% of all cases of PAH [3]. Risk factors include female gender and autoimmune hepatitis [4]. Approximately 10% of PoPH patients have portal hypertension without cirrhosis, this picture is often seen in those infected with Schistosoma mansoni [5].

Pathophysiology

The pathogenesis of PoPH, while not fully elucidated, likely involves several interconnected mechanisms. The hyperdynamic circulation associated with portal hypertension serves as a foundation for pulmonary vascular alterations [6].

A key factor is the disruption of vasoactive substance balance in the pulmonary circulation. Increased levels of vasoconstrictors (endothelin-1, thromboxane A2, serotonin) and decreased vasodilators (nitric oxide, prostacyclin) shift the balance towards vasoconstriction, elevating pulmonary vascular resistance (PVR) [1, 7, 8].

Simultaneously, pulmonary vascular remodelling occurs, triggered by chronic exposure to gut-derived toxins, inflammatory cytokines, and proangiogenic factors circulating due to altered portal blood flow [6]. These combined mechanisms - hyperdynamic circulation, vasoactive imbalance, and vascular remodelling - lead to increased PVR and subsequent right ventricular strain, culminating in the clinical presentation of PoPH.

Clinical Presentation

Symptoms of PoPH can be nonspecific and may overlap with those of underlying liver disease:

- Dyspnoea on exertion (most common)
- Fatigue
- Chest pain
- Syncope (in advanced cases)

Physical Examination may Reveal

- Loud P2 heart sound
- Systolic murmur of tricuspid regurgitation
- Signs of right heart failure (e.g., peripheral oedema, ascites)

Diagnostic Criteria



Figure 1: Diagnostic Algorithm for Porto-Pulmonary Hypertension. PASP: Pulmonary Artery Systolic Pressure, mPAP: Mean Pulmonary Artery Pressure, PVR: Pulmonary Vascular Resistance, PH: Pulmonary Hypertension

It remains uncertain whether the severity of liver disease or the degree of portal hypertension is related to the severity of PoPH. Diagnosing PoPH requires stepwise approach which includes:
Screening: Transthoracic echocardiography is the initial screening tool, estimating pulmonary artery systolic pressure.

Confirmation: Right heart catheterization is the gold standard for diagnosis, providing direct measurements of mPAP, PVR, and PAWP.

Exclusion of other causes: Conditions such as left heart disease, chronic thromboembolic pulmonary hypertension, and respiratory diseases must be ruled out.

Management

Management of PoPH is challenging and requires a multidisciplinary approach. Management includes:

1. **Supportive Measures**
   - Supplemental Oxygen: Patients with oxygen saturation below 89% should use supplementary oxygen as per International Liver Transplantation Society (ILTS) guidelines.
   - Diuretics, commonly used to treat portal hypertension, play a crucial role in managing pulmonary hypertension and controlling volume overload [2].
2. **Specific Treatment for Pulmonary Artery Hypertension (PAH)**
   - Prostacyclin analogues (e.g., epoprostenol, iloprost)
   - Endothelin receptor antagonists (e.g., bosentan, ambrisentan)
   - Phosphodiesterase-5 inhibitors (e.g., sildenafil)
   - Soluble Guanylate Cyclase Stimulators (e.g., riociguat)
   - Calcium Channel Blockers (e.g., nifedipine, diltiazem)
3. **Liver transplantation (LT)**

The outcomes following liver transplantation show significant variability, but growing research supports the use of medical interventions to prepare patients for LT and improve pulmonary hemodynamic post-transplant in certain cases [9-11].

Table 1: Pharmacological Management of Porto-pulmonary Hypertension (PoPH): Medications, Mechanisms, and Common Side-effects.

Medication Class	Examples	Mechanism of Action	Effects on Pulmonary Hemodynamics	Common Side Effects
Prostacyclin Analogues	Epoprostenol (IV), Treprostinil (SC/IV/ inhaled), Iloprost (inhaled)	Activate prostacyclin receptor, increasing cAMP	Vasodilation, anti-proliferative effects on vascular smooth muscle	Headache, flushing, jaw pain, diarrhea, nausea, hypotension
Endothelin Receptor Antagonists	Bosentan, Ambrisentan, Macitentan	Block endothelin-1 receptors	Reduce pulmonary vascular resistance and pressure	Liver toxicity, anemia, peripheral edema, nasal congestion
Phosphodiesterase-5 Inhibitors	Sildenafil, Tadalafil	Inhibit PDE-5, increasing cGMP	Vasodilation, anti-proliferative effects	Headache, flushing, nasal congestion, visual disturbances
Soluble Guanylate Cyclase Stimulators	Riociguat	Stimulate soluble guanylate cyclase, increasing cGMP	Vasodilation, anti-proliferative and anti-fibrotic effects	Hypotension, dizziness, gastrointestinal upset
Calcium Channel Blockers	Nifedipine, Diltiazem, Amlodipine	Block calcium channels in vascular smooth muscle	Vasodilation (in responders)	Peripheral edema, hypotension, headache



Figure 2: Management algorithm of Porto-pulmonary Hypertension. mPAP: Mean Pulmonary Artery Pressure, PVR: Pulmonary Vascular Resistance, WU: Wood Unit, PoPH: Porto-Pulmonary Hypertension, PAH: Pulmonary Artery Hypertension, OLT: Orthotopic Liver Transplantation, MELD: Model for End-Stage Liver Disease.

For patients with Porto pulmonary hypertension, LT is typically considered when their initial mean pulmonary arterial pressure (mPAP) is below 35 mmHg, although mild PoPH alone is not a reason for transplantation [12]. Medical optimization is recommended first for PoPH patients with mPAP of 35 mmHg or higher. They may be considered for liver transplant listing and given MELD exception points if treatment reduces their mPAP to less than 35 mmHg and pulmonary vascular resistance to under 5 Wood units. The ERS Task Force considers an mPAP of 45 mmHg or higher an absolute contraindication for transplant, though some centres use a threshold of 50 mmHg [12].

Prognosis

Patients with Porto pulmonary hypertension tend to have poorer outcomes compared to those with other Group 1 pulmonary arterial hypertension (PAH) types [13, 14]. A study using data from the REVEAL Registry found that PoPH patients had lower survival rates at 2 years (67% vs. 85%) and 5 years (40% vs. 64%) than those with idiopathic and familial PAH, despite initially showing better hemodynamic and functional assessments [14]. Similarly, in the UK, 1-year, 3-year, and 5-year survival rates for PoPH patients were 85%, 60%, and 35%, respectively, which are lower than the rates for idiopathic PAH [13].

The Prognosis of PoPH is Influenced by Several key Factors:

- Severity of pulmonary hypertension
- Right ventricular function
- Response to medical therapy
- Possibility of liver transplantation

While successful liver transplantation can lead to significant improvement of PoPH in some patients, this outcome is not universal.

Illustrative Case Study: Porto-Pulmonary Hypertension in a Patient with Chronic Kidney Disease

A 46-year-old male patient, was referred to the liver clinic with recent onset of increased abdominal girth and chest tightness. His medical history was significant for chronic kidney disease (attributed to chronic reflux nephropathy), two failed cadaveric renal transplants necessitating regular home dialysis, and a history of coronary artery disease with previous myocardial infarction and coronary bypass surgery.

On physical examination, the patient presented with signs suggestive of both chronic liver disease and pulmonary hypertension. Notably, he had splenomegaly, and massive ascites. Cardiac examination revealed atrial fibrillation, jugular venous distension, loud P2 heart sound and murmurs consistent with tricuspid regurgitation.

Laboratory investigations showed normal liver synthetic function (albumin 40 g/L, International normalised ratio (INR) 1.2) but elevated Gamma-glutamyl transpeptidase (GGT) 217 U/L (5-50 U/L). Ascitic fluid analysis was consistent with portal hypertension (Serum-Ascites Albumin Gradient (SAAG) > 1.1 g/L). Magnetic Resonance Cholangiopancreatography (MRCP) suggested cirrhosis, and upper endoscopy revealed oesophageal varices.

Echocardiography demonstrated severe pulmonary hypertension with an estimated (Right Ventricular Systolic Pressure) RVSP of 91 mmHg, along with right ventricular dilation and impairment. Right heart catheterization confirmed severe pulmonary hypertension with a mean pulmonary artery pressure of 47 mmHg and elevated pulmonary vascular resistance (PVR) of 5.5 Wood units. Notably, administration of iloprost during catheterization resulted in a significant drop in mean pulmonary artery pressure to 39 mmHg and PVR to 2.7 Wood units.

The patient was diagnosed with Porto-pulmonary Hypertension (PoPH) based on the presence of portal hypertension, elevated mean pulmonary artery pressure, and increased pulmonary vascular resistance. Initial management focused on treating ascites with salt restriction and diuretics, along with therapeutic paracentesis.

This Case Illustrates Several key Points

1. The complex interplay between liver disease, kidney disease, and pulmonary vascular complications.
2. The importance of comprehensive cardiac evaluation in patients with liver disease, especially when considering liver transplantation.
3. The potential reversibility of pulmonary hypertension with vasodilator therapy, as demonstrated by the response to iloprost.
4. The challenge of managing patients with multiple organ system involvement, necessitating consideration for dual organ transplantation.

The patient was subsequently worked up for dual liver and kidney transplantation, highlighting the complex decision-making process in managing patients with PoPH and concomitant end-stage renal disease.

Hepatopulmonary Syndrome (HPS)

To provide practical context to the discussion of HPS, we will present a relevant case study later in this section.

Definition and Epidemiology

HPS is defined as the combination of abnormal arterial oxygenation and intrapulmonary vascular dilatations in liver disease or portal hypertension patients.

The prevalence of HPS in patients with cirrhosis has been reported to range from 4% to 19% [15]. While intrapulmonary vascular dilations (IPVD) are present in 40-60% of chronic liver disease patients, only 15-30% develop the hypoxemia that fulfills HPS diagnostic criteria [16].

Pathophysiology

The primary driver of Hepatopulmonary Syndrome (HPS) is the development of intrapulmonary vascular dilatations (IPVDs). These IPVDs lead to a complex hemodynamic state, resulting in ventilation-perfusion mismatch and hypoxemia. This occurs within a hyperdynamic circulatory state, featuring increased cardiac output and low pulmonary vascular resistance, despite normal or low pulmonary artery pressures.

The IPVDs impair gas exchange through three main mechanisms:

1. Ventilation/Perfusion (V/Q) Mismatch
2. Diffusion Limitation
3. Direct Arteriovenous (AV) Communications

Other Contributing Factors Include

A. Endothelin-1 (ET-1) Pathway: Increased ET-1 in cirrhosis activates pulmonary ETB receptors, increasing nitric oxide and causing vasodilation and abnormal blood flow [17, 18].
B. Bacterial Translocation: Gut barrier breakdown allows bacteria/endotoxins to enter circulation, triggering inflammatory factors in the lungs [19-22].
C. Pulmonary Angiogenesis: Genetic factors like endoglin and vWF (Von-Willebrand Factor) polymorphisms are linked to HPS risk. Animal studies show placental growth factor (PIGF) mediates hypoxemia and shunting [23-25].

Clinical Presentation

Hepatopulmonary syndrome typically develops in patients with cirrhosis and portal hypertension, but it can also arise in those with acute or chronic liver disease, Budd-Chiari syndrome, and various vascular abnormalities that alter blood flow between the liver and lungs, such as Cavo pulmonary shunts and Abernethy malformation [18]. The presence and severity of HPS do not necessarily correspond with the severity of the underlying liver disease.

Patients with HPS typically present with dyspnoea, platypnea (worsening of dyspnoea in the upright position), and orthodeoxia (decrease in oxygen saturation ≥5% with upright position). Platypnea and orthodeoxia are more sensitive and specific indicators for diagnosing HPS, although they are not definitive on their own. Other common symptoms include fatigue, cyanosis, and clubbing of the fingers. Physical examination may reveal spider angiomata and signs of liver disease, such as ascites and splenomegaly.

The severity of HPS is classified based on the degree of hypoxemia and alveolar-arterial oxygen gradient (A-aO2) on room air [26]:
Mild: Pao2 ≥80 mmHg on room air with A-aO2 ≥15 mm Hg on room air
Moderate: PaO2 ≥60 mm Hg to <80 mm Hg with A-aO2 ≥15 mm Hg on room air
Severe: PaO2 ≥50 mm Hg to <60 mm Hg with A-aO2 ≥15 mm Hg on room air
Very Severe: PaO2 <50 mm Hg with A-aO2 ≥15 mm Hg on room air, or PaO2 <300 mm Hg while breathing 100% oxygen

Diagnostic Criteria

The diagnosis of HPS is made based on the following criteria:

1. Underlying Liver disease or Portal Hypertension with or without cirrhosis
2. Impaired oxygenation, defined as:
   - PaO2 < 80 mmHg on room air or
   - Alveolar-arterial oxygen gradient > 15 mmHg (or > 20 mmHg if age > 65 years) on room air
3. Evidence of intrapulmonary vascular dilatations, typically demonstrated by contrast-enhanced echocardiography or nuclear medicine scanning



Figure 3: Diagnostic Algorithm for Hepatopulmonary Syndrome. IPVD: Intrapulmonary Vascular Dilatation, ABG: Arterial Blood Gas.

Management

The mainstay of treatment for HPS is liver transplantation, which has been shown to improve oxygenation and reverse the underlying pathology in many patients. However, the management of HPS is complex, and several adjunctive therapies may be considered.



Figure 4: Management Algorithm of Hepatopulmonary Syndrome (HPS). ABG: Arterial Blood Gas, TTE: Trans Thoracic Echocardiography, IPVD: Intrapulmonary Vascular Dilatation.

Liver Transplant

Patients with hepatopulmonary syndrome (HPS) have a 5-year post-liver transplantation (LT) survival rate of 76%, similar to that of cirrhotic patients without HPS [27]. LT has shown to significantly improve HPS in most patients, achieving complete resolution in approximately 95% of cases, mostly within 6 to 12 months, with good overall survival rates [28, 29].

Adjunctive Therapies

- Supplemental oxygen
- Supportive care for associated complications (e.g., renal dysfunction, portal hypertension)
- Coil embolization of arteriovenous malformations is a possible palliative treatment option for the patients not eligible for Liver transplant [30].

Prognosis

Untreated Hepatopulmonary Syndrome (HPS) carries a poor prognosis. Studies show a median survival of 10.6 months for cirrhotic patients with HPS compared to 40.8 months in cirrhotic patients without HPS [31]. Liver transplantation significantly improves outcomes, with a 5-year post-transplant survival rate of 76% and complete resolution of HPS occurring in about 85% of patients within 6-12 months post-transplantation [28, 32].

Factors associated with a worse prognosis include severity of hypoxemia, degree of intrapulmonary shunting, and presence of another organ dysfunction.

Illustrative Case Study: Hepatopulmonary Syndrome Presenting with Acute Liver Injury and Budd-Chiari Syndrome

A 30-year-old female patient presented to the emergency department with complaints of dyspnoea and dizziness. She had no significant past medical history, was not on any medications, and had an unremarkable obstetric history with two healthy children.

On physical examination, the patient was found to be hypotensive with a blood pressure of 90/60 mmHg and tachycardic at 110 beats per minute. Her oxygen saturation was 88% on a rebreather mask. Abdominal examination revealed a tender, palpable liver, but no other signs of chronic liver disease were evident.

Initial Investigations Revealed the Following

- Computed tomography pulmonary angiography (CTPA) confirmed the presence of a massive pulmonary embolism.
- Laboratory tests showed elevated liver enzymes [Aspartate transaminase (AST) 1500 U/L (5-30 U/L), Alanine transaminase (ALT) 1800 U/L (5-35 U/L)], hyperbilirubinemia [total bilirubin 50 µmol/L (1-20 µmol/L)], and acute kidney injury [creatinine 300 µmol/L (45-90 µmol/L)].
- Doppler ultrasound demonstrated veno-occlusive disease of the hepatic veins and inferior vena cava, consistent with Budd-Chiari syndrome.

The patient was admitted to the intensive care unit and received anticoagulation, vasopressors, and empiric antibiotics for suspected sepsis. However, her hypoxemia persisted, requiring high-flow oxygen therapy with a fraction of inspired oxygen (FiO2) of 50%.

Further Evaluation Revealed the Following

- Arterial blood gas analysis showed a partial pressure of oxygen (PaO2) of 20 mmHg, with a widened alveolar-arterial oxygen gradient.
- Transthoracic echocardiography demonstrated a hemodynamically significant patent foramen ovale with reversed right-to-left shunting.
- Bubble contrast echocardiography was then performed, which showed a delayed and dispersed appearance of the bubbles in the left heart chambers, this pattern confirmed the presence of an additional intrapulmonary shunt component.

Based on these findings, the patient was diagnosed with Hepatopulmonary Syndrome (HPS) in the context of acute liver injury and Budd-Chiari syndrome.

Despite maximal supportive measures, the patient's hypoxemia remained refractory, needing mechanical ventilation, highlighting the severity of her condition. The patient was discussed with the liver transplant centre and subsequently transferred for further evaluation and management.

This case illustrates the importance of maintaining a high index of suspicion for HPS, even in patients without a known history of chronic liver disease. The atypical presentation, with acute liver injury and Budd-Chiari syndrome, underscores the need for a comprehensive evaluation, including contrast-enhanced echocardiography, to establish the diagnosis of HPS. The patient's rapidly progressive respiratory failure and the requirement for advanced interventions, such as mechanical ventilation, emphasize the critical nature of this complication and the need for timely recognition and management.

Discussion and Comparison of PoPH and HPS

Porto-pulmonary Hypertension (PoPH) and Hepatopulmonary Syndrome (HPS) are distinct pulmonary vascular complications associated with liver disease, presenting unique challenges in diagnosis and management.

Table 2: Comparison of Porto-pulmonary Hypertension and Hepatopulmonary Syndrome: Key Features and Distinctions

Characteristic	Portopulmonary Hypertension (PoPH)	Hepatopulmonary Syndrome (HPS)
Definition	Pulmonary arterial hypertension with portal hypertension	Vascular dilatation in lungs causing gas exchange issues
Pathophysiology	Vascular remodelling, Increased pulmonary resistance	Intrapulmonary vascular dilatations, shunting
Key Symptoms	Dyspnoea, fatigue, chest pain	Dyspnoea, platypnea, orthodeoxia
Diagnosis	Right heart catheterization	Contrast echocardiography
Main Treatment	Vasodilators, liver transplantation	Oxygen therapy, liver transplantation

Pathophysiological and Clinical Differences

PoPH is characterized by pulmonary arterial hypertension driven by portal hypertension, leading to increased pulmonary vascular resistance and right ventricular strain. In contrast, HPS involves intrapulmonary vascular dilatations, resulting in ventilation-perfusion mismatch and right-to-left shunting.

While both conditions present with dyspnea and fatigue, PoPH patients may exhibit signs of right heart failure, such as peripheral edema and jugular venous distension. HPS patients often experience platypnea and orthodeoxia, unique features that distinguish it from PoPH.

Diagnostic Approaches

PoPH is primarily diagnosed through right heart catheterization, confirming pulmonary arterial hypertension. HPS diagnosis relies on demonstrating intrapulmonary vascular dilatations, typically using contrast-enhanced echocardiography or nuclear medicine scans.

Management Strategies and Outcomes

Treatment approaches differ significantly. PoPH may be managed with pulmonary vasodilators, while liver transplantation is considered in selected cases. For HPS, liver transplantation is the mainstay of treatment, potentially reversing the underlying pathophysiology and improving oxygenation. Although liver transplantation can improve prognosis in both conditions, the magnitude of benefit appears greater for HPS patients.

Case Studies and Clinical Implications

Our case studies illustrate the diverse presentations of these conditions. The PoPH case demonstrated classic signs of pulmonary hypertension, while the HPS case presented with atypical acute liver injury and Budd-Chiari syndrome, emphasizing the need for high clinical suspicion even in non-traditional settings.

Future Directions and Challenges

Despite progress in understanding these conditions, challenges persist in early diagnosis and optimizing liver transplantation timing. Future research should focus on enhancing detection methods, refining risk stratification, and developing novel therapies. Collaborative efforts among hepatologists, pulmonologists, and cardiologists will be crucial in advancing management strategies [33].

Conclusion

This review highlights the critical distinctions between Porto-pulmonary Hypertension (PoPH) and Hepatopulmonary Syndrome (HPS) in liver disease. Recognizing their unique pathophysiological mechanisms, clinical presentations, and management approaches is essential for optimal patient care.

While liver transplantation is central to treatment for both, specific strategies differ. PoPH often requires pulmonary vasodilators and careful transplant selection, whereas HPS may be reversed by transplantation alone. Ongoing research and multidisciplinary collaboration are vital to enhance early detection, refine risk stratification, and develop novel interventions. By maintaining a comprehensive understanding of PoPH and HPS, clinicians can provide more effective, personalized care, ultimately improving outcomes and reducing the burden of these complex disorders in patients with liver disease.

References

1. Porres Aguilar M, Altamirano JT, Torre Delgadillo A, Michael R Charlton, Andres Duarte-Rojo (2012) Portopulmonary hypertension and hepatopulmonary syndrome: a clinician-oriented overview. European Respiratory Review 21: 223-233.
2. Humbert M, Kovacs G, Hoeper MM, Roberto Badagliacca, Rolf M F Berger, et al. (2022) 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J Eur Heart J 43: 3618-3731.
3. Shao Y, Yin X, Qin T, Ruihua Zhang, Yu Zhang, et al. (2021) Prevalence and associated factors of portopulmonary hypertension in patients with portal hypertension: a case-control study. Biomed Res Int 2021: 5595614.
4. Kawut SM, Krowka MJ, Trotter JF, Kari E Roberts, Raymond L Benza, et al. (2008) Clinical risk factors for portopulmonary hypertension. Hepatology 48: 196-203.
5. Safdar Z, Bartolome S, Sussman N (2012) Portopulmonary hypertension: An update. Liver Transplantation 18: 881-891.
6. Talwalkar JA, Swanson KL, Krowka MJ, James C Andrews, Patrick S Kamath (2011) Prevalence of Spontaneous Portosystemic Shunts in Patients with Portopulmonary Hypertension and Effect on Treatment. Gastroenterology 141: 1673-1679.
7. Huertas A, Guignabert C, Barberà JA, Peter Bärtsch, Jahar Bhattacharya, et al. (2018) Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases. European

Respiratory Journal 51: 1700745.
8. Shenoda B, Boselli J (2019) Vascular syndromes in liver cirrhosis. Clinical Journal of Gastroenterology 12: 387-397.
9. Krowka MJ, Mandell MS, Ramsay MAE, Steve M Kawut, Michael B Fallon, et al. (2004) Hepatopulmonary syndrome and portopulmonary hypertension: A report of multicenter liver transplant database. Liver Transplant 10: 174-182.
10. Swanson KL, Wiesner RH, Nyberg SL, C B Rosen, M J Krowka (2008) Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant 8: 2445-2453.
11. Ashfaq M, Chinnakotla S, Rogers L, K Ausloos, S Saadeh, et al. (2007) The impact of treatment of portopulmonary hypertension on survival following liver transplantation. Am J Transplant 7: 1258-1264.
12. Krowka MJ, Fallon MB, Kawut SM, Valentin Fuhrmann, Julie K Heimbach, et al. (2016) International liver transplant society practice guidelines: Diagnosis and management of hepatopulmonary syndrome and portopulmonary hypertension. Transplantation 100: 1440-1452.
13. Sithamparanathan S, Nair A, Thirugnanasothy L, J Gerry Coghlan, Robin Condliffe, et al. (2017) Survival in portopulmonary hypertension: Outcomes of the United Kingdom National Pulmonary Arterial Hypertension Registry. The Journal of Heart and Lung Transplantation 36: 770-779.
14. Krowka MJ, Miller DP, Barst RJ, Darren Taichman, Raed A Dweik, et al. (2012) Portopulmonary Hypertension. Chest 141: 906-915.
15. Schenk P, Fuhrmann V, Madl C, G Funk, S Lehr, et al. (2002) Hepatopulmonary syndrome: prevalence and predictive value of various cut offs for arterial oxygenation and their clinical consequences. Gut 51: 853-859.
16. Abrams GA, Jaffe CC, Hoffer PB, H J Binder, M B Fallon (1995) Diagnostic utility of contrast echocardiography and lung perfusion scan in patients with hepatopulmonary syndrome. Gastroenterology 109: 1283-1288.
17. Rolla G (2004) Hepatopulmonary syndrome: role of nitric oxide and clinical aspects. Digestive and Liver Disease. 36: 303-308.
18. Raevens S, Boret M, Fallon MB. Hepatopulmonary syndrome. JHEP Reports. 2022 Sep; 4:100527.
19. Sztrymf B, Rabiller A, Nunes H, L Savale, D Lebrec, et al. (2004) Prevention of hepatopulmonary syndrome and hyperdynamic state by pentoxifylline in cirrhotic rats. Eur Respir J 23: 752-758.
20. Thenappan T, Goel A, Marsboom G, Yong-Hu Fang, Peter T Toth, et al. (2011) A central role for CD68(+) macrophages in hepatopulmonary syndrome. Reversal by macrophage depletion. Am J Respir Crit Care Med 183: 1080-1091.
21. Sztrymf B, Libert JM, Mougeot C, Didier Lebrec, Michel Mazmanian, et al. (2005) Cirrhotic rats with bacterial translocation have higher incidence and severity of hepatopulmonary syndrome. J Gastroenterol Hepatol 20: 1538-1544.
22. Fouts DE, Torralba M, Nelson KE, David A Brenner, Bernd Schnabl (2012) Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. J Hepatol 56: 1283-1292.
23. Kochar R, Rajasekhar Tanikella, Fallon MB (2011) Serial Pulse Oximetry in Hepatopulmonary Syndrome. Digestive Diseases and Sciences 56: 1862-1868.
24. Zhang J, Luo B, Tang L, Yongming Wang, Cecil R Stockard, et al. (2009) Pulmonary Angiogenesis in a Rat Model of Hepatopulmonary Syndrome. Gastroenterology 136:1070-1080.
25. Raevens S, Geerts A, Annelies Paridaens, Sander Lefere, Xavier Verhelst, et al. (2018) Placental growth factor inhibition targets pulmonary angiogenesis and represents a therapy for hepatopulmonary syndrome in mice†. Hepatology 68: 634-651.
26. Bansal K, Gore M, Mittal S (2021) Hepatopulmonary Syndrome. PubMed. Treasure Island: StatPearls https://www.ncbi.nlm.nih.gov/books/NBK562169/.
27. Swanson KL, Wiesner RH, Krowka MJ (2005) Natural history of hepatopulmonary syndrome: impact of liver transplantation. Hepatology 41: 1122-1129.
28. Arguedas MR, Abrams GA, Krowka MJ, Michael B Fallon (2003) Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation. Hepatology 37: 192-197.
29. Aragon Pinto C, Iyer VN, Albitar HAH, Alexandra Anderson, Hector Cajigas, et al. (2021) Outcomes of liver transplantation in patients with hepatopulmonary syndrome in the pre- and post-MELD eras: a systematic review. Respir Med Res 80: 100852.
30. Grady K, Gowda S, Kingah P, Ayman O Soubani (2015) Coil Embolization of Pulmonary Arteries as a Palliative Treatment of Diffuse Type I Hepatopulmonary Syndrome. Respiratory Care 60: e20-5.
31. Schenk P, Schöniger-Hekele M, Fuhrmann V, Madl C, Silberhumer G, et al. (2003) Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology 125: 1042-1052.
32. Gupta S, Castel H, Rao RV, M Picard, L Lilly, et al. (2010) Improved survival after liver transplantation in patients with hepatopulmonary syndrome. Am J Transplant 10: 354-363.
33. EA Jasso-Baltazar, Peña-Arellano GA, Aguirre-Valadez J, Ruiz I, B Papacristofilou-Riebeling, et al. (2003) Portopulmonary Hypertension: An Updated Review. Transplantation Direct 9: e1517.